

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

MICHAEL SOOKDEO, Individually and on
Behalf of All Others Similarly Situated,

Plaintiff,

v.

HIMS & HERS HEALTH, INC., ANDREW
DUDUM, and OLUYEMI OKUPE,

Defendant.

Case No.

**CLASS ACTION COMPLAINT FOR
VIOLATIONS OF THE FEDERAL
SECURITIES LAWS**

DEMAND FOR JURY TRIAL

Plaintiff Michael Sookdeo (“Plaintiff”), individually and on behalf of all others similarly situated, by and through his attorneys, alleges the following upon information and belief, except as to those allegations concerning Plaintiff, which are alleged upon personal knowledge. Plaintiff’s information and belief is based upon, among other things, his counsel’s investigation, which includes without limitation: (a) review and analysis of regulatory filings made by Hims & Hers Health, Inc. (“Hims” or the “Company”) with the United States (“U.S.”) Securities and Exchange Commission (“SEC”); (b) review and analysis of press releases and media reports issued by and disseminated by Hims; and (c) review of other publicly available information concerning Hims.

NATURE OF THE ACTION AND OVERVIEW

1. This is a class action on behalf of persons and entities that purchased or otherwise acquired Hims securities between April 29, 2025 and June 22, 2025, inclusive (the “Class Period”). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the “Exchange Act”).

2. Hims operates a telehealth platform that connects consumers to licensed healthcare professionals. The Company’s platform offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. In May 2024, the Company began providing access to compounded injectable semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), used for weight loss.

3. On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of “a bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform.”

4. On June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, “*based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.*”¹ The press release stated that Hims “*has failed to adhere to the law which prohibits mass*

¹ Unless otherwise stated, all emphasis in bold and italics herein is added.

1 *sales of compounded drugs under the false guise of 'personalization.'*” The press release further
 2 stated “[b]ased on Novo Nordisk’s investigation, the ‘semaglutide’ active pharmaceutical
 3 ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies
 4 are manufactured by foreign suppliers in China” which “FDA has never authorized or approved”
 5 and which may contain “unsafe and illicit foreign ingredients.”

6 5. On this news, the Company’s share price fell \$22.24, or 34.6%, to close at \$41.98
 7 per share on June 23, 2025, on unusually heavy trading volume.

8 6. Throughout the Class Period, Defendants made materially false and/or misleading
 9 statements, as well as failed to disclose material adverse facts about the Company’s business,
 10 operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Hims was
 11 engaged in the “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that
 12 put patient safety at risk;” (2) that, as a result, there was a substantial risk that the Company’s
 13 collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing,
 14 Defendants’ positive statements about the Company’s business, operations, and prospects were
 15 materially misleading and/or lacked a reasonable basis.

16 7. As a result of Defendants’ wrongful acts and omissions, and the precipitous decline
 17 in the market value of the Company’s securities, Plaintiff and other Class members have suffered
 18 significant losses and damages.

19 **JURISDICTION AND VENUE**

20 8. The claims asserted herein arise under Sections 10(b) and 20(a) of the Exchange Act
 21 (15 U.S.C. §§ 78j(b) and 78t(a)) and Rule 10b-5 promulgated thereunder by the SEC (17 C.F.R. §
 22 240.10b-5).

23 9. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C.
 24 § 1331 and Section 27 of the Exchange Act (15 U.S.C. § 78aa).

25 10. Venue is proper in this Judicial District pursuant to 28 U.S.C. § 1391(b) and Section
 26 27 of the Exchange Act (15 U.S.C. § 78aa(c)). Substantial acts in furtherance of the alleged fraud
 27 or the effects of the fraud have occurred in this Judicial District. Many of the acts charged herein,
 28 including the dissemination of materially false and/or misleading information, occurred in

1 substantial part in this Judicial District. In addition, the Company's principal executive offices are
2 located in this District.

3 11. In connection with the acts, transactions, and conduct alleged herein, Defendants
4 directly and indirectly used the means and instrumentalities of interstate commerce, including the
5 United States mail, interstate telephone communications, and the facilities of a national securities
6 exchange.

7 **PARTIES**

8 12. Plaintiff Michael Sookdeo, as set forth in the accompanying certification,
9 incorporated by reference herein, purchased Hims securities during the Class Period, and suffered
10 damages as a result of the federal securities law violations and false and/or misleading statements
11 and/or material omissions alleged herein.

12 13. Defendant Hims is incorporated under the laws of Delaware with its principal
13 executive offices located in San Francisco, California. Hims's common stock trades on the New
14 York Stock Exchange ("NYSE") under the symbol "HIMS."

15 14. Defendant Andrew Dudum ("Dudum") was the Company's Chief Executive Officer
16 ("CEO") at all relevant times.

17 15. Defendant Oluyemi Okupe ("Okupe") was the Company's Chief Financial Officer
18 ("CFO") at all relevant times.

19 16. Defendants Dudum and Okupe (collectively the "Individual Defendants"), because
20 of their positions with the Company, possessed the power and authority to control the contents of
21 the Company's reports to the SEC, press releases and presentations to securities analysts, money
22 and portfolio managers and institutional investors, i.e., the market. The Individual Defendants were
23 provided with copies of the Company's reports and press releases alleged herein to be misleading
24 prior to, or shortly after, their issuance and had the ability and opportunity to prevent their issuance
25 or cause them to be corrected. Because of their positions and access to material non-public
26 information available to them, the Individual Defendants knew that the adverse facts specified
27 herein had not been disclosed to, and were being concealed from, the public, and that the positive
28

representations which were being made were then materially false and/or misleading. The Individual Defendants are liable for the false statements pleaded herein.

SUBSTANTIVE ALLEGATIONS

Background

17. Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The Company's platform offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. In May 2024, the Company began providing access to compounded injectable semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), used for weight loss.

Materially False and Misleading

Statements Issued During the Class Period

18. The Class Period begins on April 29, 2025. On that date, Hims issued a press release which announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform." Specifically, the press release stated as follows, in relevant part:

Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care

* * *

A bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform marks the first step in a long-term collaboration roadmap, pairing innovative treatments with a leading care platform to elevate the impact of obesity care for today's consumer.

Hims & Hers Health, Inc. today announced a long-term collaboration with Novo Nordisk designed to make proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans.

As a first step, Americans can now access NovoCare® Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy® and a Hims & Hers membership, which includes access to 24/7 care, ongoing clinical support, and nutrition guidance, all in one place. At a single, unified price starting at 599 USD per month, individuals may be prescribed Wegovy®, alongside Hims & Hers' world-class, holistic approach to care, powered by today's technology. The offering is available this week on the Hims & Hers platform.

The companies are also developing a roadmap that combines Novo Nordisk's innovative treatments with Hims & Hers' ability to scale access to quality care, aiming to improve long-term outcomes for more people, more affordably.

* * *

This new offering builds on Hims & Hers' existing suite of weight loss solutions and provides access to all dose strengths of Wegovy® in a high-quality pen for self-pay patients. The platform will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans, giving patients more ways to start and sustain their health journey based on their needs, goals, and eligibility.

19. On May 5, 2025, Hims issued a press release announcing its results of operations for the quarter ended March 31, 2025. The press release touted the Company's financial results including an accelerated subscriber growth trajectory, as follows in relevant part:

Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

Revenue of \$586.0 million, up 111% year-over-year in Q1 2025

Net income of \$49.5 million; Adjusted EBITDA of \$91.1 million in Q1 2025

Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025

Affirms full year 2025 revenue guidance of \$2.3 billion to \$2.4 billion and raises Adjusted EBITDA guidance to a range of \$295 million to \$335 million

Introduces 2030 targets of at least \$6.5 billion in revenue and \$1.3 billion in Adjusted EBITDA

* * *

Key Business Metrics

(In Thousands, Except for Monthly Online Revenue per Average Subscriber, Unaudited)

	Three Months Ended March 31,		
	2025	2024	% Change
Subscribers (end of period)	2,366	1,709	38 %
Monthly Online Revenue per Average Subscriber	\$ 84	\$ 55	53 %

Revenue

(In Thousands, Unaudited)

	Three Months Ended March 31,		
	2025	2024	% Change
Online Revenue	\$576,361	\$267,761	115 %
Wholesale Revenue	9,649	10,410	(7)%
Total revenue	\$586,010	\$278,171	111 %

First Quarter 2025 Financial Highlights

•Revenue was \$586.0 million for the first quarter of 2025 compared to \$278.2 million for the first quarter of 2024, an increase of 111% year-over-year.

•Gross margin was 73% for the first quarter of 2025 compared to 82% for the first quarter of 2024.

•Net income was \$49.5 million for the first quarter of 2025 compared to \$11.1 million for the first quarter of 2024.

•Adjusted EBITDA was \$91.1 million for the first quarter of 2025 compared to \$32.3 million for the first quarter of 2024.

•Net cash provided by operating activities was \$109.1 million for the first quarter of 2025 compared to \$25.8 million for the first quarter of 2024.

•Free Cash Flow was \$50.1 million for the first quarter of 2025 compared to \$11.9 million for the first quarter of 2024.

20. On May 5, 2025, Hims issued a shareholder letter concerning the results of operations for the quarter ended March 31, 2025. The shareholder letter affirmed the previously reported financial results and touted the Company's partnership with Novo Nordisk alongside the Company's purportedly "personalized semaglutide dosage" offerings, as follows in relevant part:

Key Financial Highlights	Q1 2025 Q1 2024	Growth
Revenue	\$586M \$278M	111% YoY
Net Income	\$49M \$11M	345% YoY
Adj. EBITDA*	\$91M \$32M	182% YoY
Operating Cash Flow	\$109M \$26M	322% YoY
Free Cash Flow*	\$50M \$12M	321% YoY
Subscribers ¹ (End of Period)	2.4M 1.7M	38% YoY
Monthly Online Revenue per Avg. Subscriber	\$84 \$55	53% YoY

*

*

*

We launched innovative partnerships that set the stage for greater consumer choice within our Weight Loss specialty, providing a blueprint for future specialties

Enabling consumers to access a breadth of options has been a critical component of our strategy, and has allowed us to establish a leadership position across each of our specialties. Within our Weight Loss specialty, we recently brought more options to current and future subscribers. Oral medication kits and personalized compounded GLP-1s continue to serve our customers well, and with the launch of liraglutide at the end of March, our platform now offers access to the first generic GLP-1. This launch is already seeing early signs of success, providing subscribers previously taking commercially available dosages of semaglutide another option to transition to following the end of the semaglutide shortage.



1 *Additionally, in April we announced a long-term collaboration with Novo Nordisk*
 2 *to expand affordable access to proven obesity care. As a first step, individuals can*
 3 *now access Wegovy® through the Hims & Hers platform, bundled with access to*
 4 *24/7 care, clinical support, and nutrition guidance, all at a single, unified price.*
 5 *This collaboration pairs our customer-centric platform with Novo Nordisk's*
 6 *innovative pipeline, allowing us to serve more customers, broaden access to*
 7 *clinically proven treatments, and drive stronger outcomes.* More importantly,
 8 beyond this initial launch, we are developing a broader roadmap together with Novo
 9 Nordisk, as well as a blueprint for future partnerships, to deliver access to quality
 10 care at scale, improve long-term outcomes for people living with chronic disease,
 11 and make care more affordable.




12
13
14
15 21. On May 5, 2025, Hims issued an investor presentation concerning the results of
 16 operations for the quarter ended March 31, 2025. The investor presentation affirmed the previously
 17 reported financial results, touted the Company's partnership with Novo Nordisk alongside
 18 purportedly "personalized semaglutide dosage" offerings, and further touted the Company's
 19 purported manufacturing in "FDA and state regulated facilities and third party testing", as follows
 20 in relevant part:

STRATEGY

21 The breadth of our weight loss offering continues to
 22 expand, addressing a variety of subscriber profiles





22. On May 5, 2025, the Company submitted its quarterly report for the period ended March 31, 2025 on a Form 10-Q filed with the SEC. The quarterly report affirmed the previously reported financial results and touted the Company's online revenue as driven by personalized GLP-1 doses, as well as the Company's ability to continuing offering access to certain compounded GLP-1s pursuant to applicable FDA regulations, as follows in relevant part:

We generated \$576.4 million in Online Revenue for the three months ended March 31, 2025, an increase of \$308.6 million, or 115%, as compared to \$267.8 million for the three months ended March 31, 2024. Growth in Online Revenue for the three months ended March 31, 2025 was driven by: (i) new Subscriber growth pertaining to weight loss solutions launched in the fourth quarter of 2023 or later, including new Subscribers for compounded semaglutide glucagon-like peptide-1 receptor agonists ("GLP-1s") offerings launched in the second quarter of 2024 for which there was no comparable revenue for the three months ended March 31, 2024; and (ii) continued sustainable growth in Subscribers pertaining to offerings available in both periods, from whom we generated recurring revenue that was driven in part by ordinary-course marketing campaigns that continued to strengthen our mature offerings. ***During the three months ended March 31, 2025, our GLP-1 offerings generated approximately \$230 million in Online Revenue, a significant majority of which came from personalized doses.*** New Subscriber growth in our GLP-1 offering was driven by both ordinary-course marketing campaigns as well as a specialized marketing campaign as discussed further below. Certain aspects of our GLP-1 compounded offerings were permitted by the Food and Drug Administration ("FDA") based on shortages of branded GLP-1s, which were affected by regulatory decisions during the first quarter of 2025 as further described below. Excluding our GLP-1 offerings, the remaining Online Revenue of approximately \$346 million during the period increased nearly 30% year-over-year as a result of new Subscriber growth. During the three months ended March 31, 2025, we aired a Super Bowl

1 marketing campaign highlighting specialized offerings on our platform and building
2 brand awareness with consumers in order to normalize health and wellness
challenges, which resulted in increased traffic to our platform.

3 Online Revenue can fluctuate on a period-to-period basis due to various factors,
4 including launches of new product offerings, the success of our marketing
5 campaigns, and pricing decisions impacting customer uptake of our offerings, as well
6 as product availability and the regulatory landscape impacting our offerings. As
7 described under Part II, Item 1A: “Risk Factors”, on February 21, 2025, the FDA
8 resolved the semaglutide shortage, which has constrained and is expected to continue
9 to constrain our ability to continue providing access to compounded semaglutide on
our platform. *The FDA does not limit compounding to drug shortages, and we
believe there are paths to continue offering access to certain compounded GLP-1s
after the period of FDA enforcement discretion has ended following resolution of
the shortage, consistent with the statutory exemptions from the new drug approval
requirements. As such, we intend to continue expanding our weight loss offerings
and serving our Subscribers with a wide range of weight loss solutions.*

10 23. On May 22, 2025, the Company issued a press release announcing an additional
11 Wegovy® semaglutide offering in partnership with Novo Nordisk. The press release stated as
12 follows in relevant part:

13 **Hims & Hers Introduces 6-Month Wegovy® New Customer Offer**

14 * * *

15 SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE:
16 HIMS) today announced eligible customers can access 6 months of prescription-only
Wegovy® at a new, affordable price, making proven obesity care and treatments
more accessible, more affordable, and more connected for millions of Americans.

17 * * *

18 Starting today, new customers eligible for Wegovy® on the Hims & Hers platform
19 can access their care for \$549 per month for 6 months (for a limited-time only)1,
20 ensuring customers have a longer window to access the affordable care they need.
21 Included in that price is access to Hims & Hers’ world-class, holistic approach to
22 weight loss, powered by today's technology. Hims & Hers will continue to offer
23 access to its full breadth of weight loss treatment options, including other
24 medications, oral kits, protein, nutrition kits, and clinically-backed care plans, all of
25 which help customers start and sustain their health journey based on their needs,
26 goals, and eligibility.

27 24. The above statements identified in ¶¶18-23 were materially false and/or misleading,
28 and failed to disclose material adverse facts about the Company’s business, operations, and
prospects. Specifically, Defendants failed to disclose to investors: (1) that Hims was engaged in the
“deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient
safety at risk;” (2) that, as a result, there was a substantial risk that the Company’s collaboration

with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Disclosures at the End of the Class Period

25. On June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was ending its partnership with Hims, stating that Hims *"has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk."* The press release further stated "[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies" may contain *"unsafe and illicit foreign ingredients."* Specifically, the press release stated, as follows, in relevant part:

Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing

- Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk
- Novo Nordisk won't stop taking action to protect Americans from the dangers of illicit foreign active pharmaceutical ingredients in knock-off drugs
- Efforts will continue to make authentic, FDA-approved Wegovy® directly available through NovoCare® Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients living with chronic diseases

PLAINSBORO, N.J., June 23, 2025 /PRNewswire/ -- *Novo Nordisk announced today that the company will no longer be working with Hims & Hers Health, Inc., and that direct access to Wegovy® will no longer be available to Hims & Hers Health, Inc. via NovoCare® Pharmacy.*

In late April, the FDA resolved the Wegovy® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy® through NovoCare® Pharmacy, Novo Nordisk began collaborating with telehealth companies. *Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of "personalization" and are disseminating deceptive marketing that put patient safety at risk.*

1 "Novo Nordisk is firm on our position and protecting patients living with obesity.
 2 ***When patients are prescribed semaglutide treatments by their licensed healthcare***
 3 ***professional or a telehealth provider, they are entitled to receive authentic, FDA-***
 4 ***approved and regulated Wegovy®,"*** said Dave Moore, Executive Vice President,
 5 US Operations of Novo Nordisk Inc. "We will work with telehealth companies to
 6 provide direct access to Wegovy® that share our commitment to patient safety – and
 7 when companies engage in illegal sham compounding that jeopardizes the health of
 8 Americans, we will continue to take action."

9 Novo Nordisk is deeply concerned and is continuing to take proactive measures to
 10 keep US patients safe from knock-off drugs made with foreign illicit active
 11 pharmaceutical ingredients. ***Based on Novo Nordisk's investigation, the***
 12 ***"semaglutide" active pharmaceutical ingredients that are in the knock-off drugs***
 13 ***sold by telehealth entities and compounding pharmacies are manufactured by***
 14 ***foreign suppliers in China. According to a report from the Brookings***
 15 ***Institute, FDA has never authorized or approved the manufacturing processes***
 16 ***used by any of these foreign suppliers to make semaglutide, nor has FDA ever***
 17 ***reviewed or authorized the quality of the "semaglutide" they produce. The report***
 18 ***also found that a "large share of [these Chinese suppliers] were never inspected***
 19 ***by FDA, and many of those that were [inspected] had drug quality assurance***
 20 ***violations."*** US patients should not be exposed to knock-off drugs made with
 21 ***unsafe and illicit foreign ingredients.***

22 26. On this news, the Company's share price fell \$22.24, or 34.6%, to close at \$41.98
 23 per share on June 23, 2025, on unusually heavy trading volume.

24 CLASS ACTION ALLEGATIONS

25 27. Plaintiff brings this action as a class action pursuant to Federal Rule of Civil
 26 Procedure 23(a) and (b)(3) on behalf of a class, consisting of all persons and entities that purchased
 27 or otherwise acquired Hims securities between April 29, 2025 and June 22, 2025, inclusive, and
 28 who were damaged thereby (the "Class"). Excluded from the Class are Defendants, the officers and
 directors of the Company, at all relevant times, members of their immediate families and their legal
 representatives, heirs, successors, or assigns, and any entity in which Defendants have or had a
 controlling interest.

29 28. The members of the Class are so numerous that joinder of all members is
 impracticable. Throughout the Class Period, Hims's shares actively traded on the NYSE. While
 the exact number of Class members is unknown to Plaintiff at this time and can only be ascertained
 through appropriate discovery, Plaintiff believes that there are at least hundreds or thousands of
 members in the proposed Class. Millions of Hims shares were traded publicly during the Class
 Period on the NYSE. Record owners and other members of the Class may be identified from records

1 maintained by Hims or its transfer agent and may be notified of the pendency of this action by mail,
2 using the form of notice similar to that customarily used in securities class actions.

3 29. Plaintiff's claims are typical of the claims of the members of the Class as all members
4 of the Class are similarly affected by Defendants' wrongful conduct in violation of federal law that
5 is complained of herein.

6 30. Plaintiff will fairly and adequately protect the interests of the members of the Class
7 and has retained counsel competent and experienced in class and securities litigation.

8 31. Common questions of law and fact exist as to all members of the Class and
9 predominate over any questions solely affecting individual members of the Class. Among the
10 questions of law and fact common to the Class are:

11 (a) whether the federal securities laws were violated by Defendants' acts as
12 alleged herein;

13 (b) whether statements made by Defendants to the investing public during the
14 Class Period omitted and/or misrepresented material facts about the business, operations, and
15 prospects of Hims; and

16 (c) to what extent the members of the Class have sustained damages and the
17 proper measure of damages.

18 32. A class action is superior to all other available methods for the fair and efficient
19 adjudication of this controversy since joinder of all members is impracticable. Furthermore, as the
20 damages suffered by individual Class members may be relatively small, the expense and burden of
21 individual litigation makes it impossible for members of the Class to individually redress the wrongs
22 done to them. There will be no difficulty in the management of this action as a class action.

23 **UNDISCLOSED ADVERSE FACTS**

24 33. The market for Hims's securities was open, well-developed and efficient at all
25 relevant times. As a result of these materially false and/or misleading statements, and/or failures to
26 disclose, Hims's securities traded at artificially inflated prices during the Class Period. Plaintiff and
27 other members of the Class purchased or otherwise acquired Hims's securities relying upon the
28

1 integrity of the market price of the Company's securities and market information relating to Hims,
2 and have been damaged thereby.

3 34. During the Class Period, Defendants materially misled the investing public, thereby
4 inflating the price of Hims's securities, by publicly issuing false and/or misleading statements and/or
5 omitting to disclose material facts necessary to make Defendants' statements, as set forth herein,
6 not false and/or misleading. The statements and omissions were materially false and/or misleading
7 because they failed to disclose material adverse information and/or misrepresented the truth about
8 Hims's business, operations, and prospects as alleged herein.

9 35. At all relevant times, the material misrepresentations and omissions particularized in
10 this Complaint directly or proximately caused or were a substantial contributing cause of the
11 damages sustained by Plaintiff and other members of the Class. As described herein, during the
12 Class Period, Defendants made or caused to be made a series of materially false and/or misleading
13 statements about Hims's financial well-being and prospects. These material misstatements and/or
14 omissions had the cause and effect of creating in the market an unrealistically positive assessment
15 of the Company and its financial well-being and prospects, thus causing the Company's securities
16 to be overvalued and artificially inflated at all relevant times. Defendants' materially false and/or
17 misleading statements during the Class Period resulted in Plaintiff and other members of the Class
18 purchasing the Company's securities at artificially inflated prices, thus causing the damages
19 complained of herein when the truth was revealed.

20 **LOSS CAUSATION**

21 36. Defendants' wrongful conduct, as alleged herein, directly and proximately caused
22 the economic loss suffered by Plaintiff and the Class.

23 37. During the Class Period, Plaintiff and the Class purchased Hims's securities at
24 artificially inflated prices and were damaged thereby. The price of the Company's securities
25 significantly declined when the misrepresentations made to the market, and/or the information
26 alleged herein to have been concealed from the market, and/or the effects thereof, were revealed,
27 causing investors' losses.

1 and/or misleading statements during the Class Period resulted in Plaintiff and other members of the
2 Class purchasing the Company's securities at such artificially inflated prices, and each of them has
3 been damaged as a result.

4 41. At all relevant times, the market for Hims's securities was an efficient market for the
5 following reasons, among others:

6 (a) Hims shares met the requirements for listing, and was listed and actively
7 traded on the NYSE, a highly efficient and automated market;

8 (b) As a regulated issuer, Hims filed periodic public reports with the SEC and/or
9 the NYSE;

10 (c) Hims regularly communicated with public investors via established market
11 communication mechanisms, including through regular dissemination of press releases on the
12 national circuits of major newswire services and through other wide-ranging public disclosures,
13 such as communications with the financial press and other similar reporting services; and/or

14 (d) Hims was followed by securities analysts employed by brokerage firms who
15 wrote reports about the Company, and these reports were distributed to the sales force and certain
16 customers of their respective brokerage firms. Each of these reports was publicly available and
17 entered the public marketplace.

18 42. As a result of the foregoing, the market for Hims's securities promptly digested
19 current information regarding Hims from all publicly available sources and reflected such
20 information in Hims's share price. Under these circumstances, all purchasers of Hims's securities
21 during the Class Period suffered similar injury through their purchase of Hims's securities at
22 artificially inflated prices and a presumption of reliance applies.

23 43. A Class-wide presumption of reliance is also appropriate in this action under the
24 Supreme Court's holding in *Affiliated Ute Citizens of Utah v. United States*, 406 U.S. 128 (1972),
25 because the Class's claims are, in large part, grounded on Defendants' material misstatements and/or
26 omissions. Because this action involves Defendants' failure to disclose material adverse
27 information regarding the Company's business operations and financial prospects—information that
28 Defendants were obligated to disclose—positive proof of reliance is not a prerequisite to recovery.

1 All that is necessary is that the facts withheld be material in the sense that a reasonable investor
 2 might have considered them important in making investment decisions. Given the importance of
 3 the Class Period material misstatements and omissions set forth above, that requirement is satisfied
 4 here.

5 **NO SAFE HARBOR**

6 44. The statutory safe harbor provided for forward-looking statements under certain
 7 circumstances does not apply to any of the allegedly false statements pleaded in this Complaint. The
 8 statements alleged to be false and misleading herein all relate to then-existing facts and conditions.
 9 In addition, to the extent certain of the statements alleged to be false may be characterized as forward
 10 looking, they were not identified as “forward-looking statements” when made and there were no
 11 meaningful cautionary statements identifying important factors that could cause actual results to
 12 differ materially from those in the purportedly forward-looking statements. In the alternative, to the
 13 extent that the statutory safe harbor is determined to apply to any forward-looking statements
 14 pleaded herein, Defendants are liable for those false forward-looking statements because at the time
 15 each of those forward-looking statements was made, the speaker had actual knowledge that the
 16 forward-looking statement was materially false or misleading, and/or the forward-looking statement
 17 was authorized or approved by an executive officer of Hims who knew that the statement was false
 18 when made.

19 **FIRST CLAIM**

20 **Violation of Section 10(b) of The Exchange Act and**

21 **Rule 10b-5 Promulgated Thereunder**

22 **Against All Defendants**

23 45. Plaintiff repeats and re-alleges each and every allegation contained above as if fully
 24 set forth herein.

25 46. During the Class Period, Defendants carried out a plan, scheme and course of conduct
 26 which was intended to and, throughout the Class Period, did: (i) deceive the investing public,
 27 including Plaintiff and other Class members, as alleged herein; and (ii) cause Plaintiff and other
 28 members of the Class to purchase Hims’s securities at artificially inflated prices. In furtherance of

1 this unlawful scheme, plan and course of conduct, Defendants, and each defendant, took the actions
2 set forth herein.

3 47. Defendants (i) employed devices, schemes, and artifices to defraud; (ii) made untrue
4 statements of material fact and/or omitted to state material facts necessary to make the statements
5 not misleading; and (iii) engaged in acts, practices, and a course of business which operated as a
6 fraud and deceit upon the purchasers of the Company's securities in an effort to maintain artificially
7 high market prices for Hims's securities in violation of Section 10(b) of the Exchange Act and Rule
8 10b-5. All Defendants are sued either as primary participants in the wrongful and illegal conduct
9 charged herein or as controlling persons as alleged below.

10 48. Defendants, individually and in concert, directly and indirectly, by the use, means or
11 instrumentalities of interstate commerce and/or of the mails, engaged and participated in a
12 continuous course of conduct to conceal adverse material information about Hims's financial well-
13 being and prospects, as specified herein.

14 49. Defendants employed devices, schemes and artifices to defraud, while in possession
15 of material adverse non-public information and engaged in acts, practices, and a course of conduct
16 as alleged herein in an effort to assure investors of Hims's value and performance and continued
17 substantial growth, which included the making of, or the participation in the making of, untrue
18 statements of material facts and/or omitting to state material facts necessary in order to make the
19 statements made about Hims and its business operations and future prospects in light of the
20 circumstances under which they were made, not misleading, as set forth more particularly herein,
21 and engaged in transactions, practices and a course of business which operated as a fraud and deceit
22 upon the purchasers of the Company's securities during the Class Period.

23 50. Each of the Individual Defendants' primary liability and controlling person liability
24 arises from the following facts: (i) the Individual Defendants were high-level executives and/or
25 directors at the Company during the Class Period and members of the Company's management team
26 or had control thereof; (ii) each of these defendants, by virtue of their responsibilities and activities
27 as a senior officer and/or director of the Company, was privy to and participated in the creation,
28 development and reporting of the Company's internal budgets, plans, projections and/or reports;

1 (iii) each of these defendants enjoyed significant personal contact and familiarity with the other
2 defendants and was advised of, and had access to, other members of the Company's management
3 team, internal reports and other data and information about the Company's finances, operations, and
4 sales at all relevant times; and (iv) each of these defendants was aware of the Company's
5 dissemination of information to the investing public which they knew and/or recklessly disregarded
6 was materially false and misleading.

7 51. Defendants had actual knowledge of the misrepresentations and/or omissions of
8 material facts set forth herein, or acted with reckless disregard for the truth in that they failed to
9 ascertain and to disclose such facts, even though such facts were available to them. Such defendants'
10 material misrepresentations and/or omissions were done knowingly or recklessly and for the purpose
11 and effect of concealing Hims's financial well-being and prospects from the investing public and
12 supporting the artificially inflated price of its securities. As demonstrated by Defendants'
13 overstatements and/or misstatements of the Company's business, operations, financial well-being,
14 and prospects throughout the Class Period, Defendants, if they did not have actual knowledge of the
15 misrepresentations and/or omissions alleged, were reckless in failing to obtain such knowledge by
16 deliberately refraining from taking those steps necessary to discover whether those statements were
17 false or misleading.

18 52. As a result of the dissemination of the materially false and/or misleading information
19 and/or failure to disclose material facts, as set forth above, the market price of Hims's securities was
20 artificially inflated during the Class Period. In ignorance of the fact that market prices of the
21 Company's securities were artificially inflated, and relying directly or indirectly on the false and
22 misleading statements made by Defendants, or upon the integrity of the market in which the
23 securities trades, and/or in the absence of material adverse information that was known to or
24 recklessly disregarded by Defendants, but not disclosed in public statements by Defendants during
25 the Class Period, Plaintiff and the other members of the Class acquired Hims's securities during the
26 Class Period at artificially high prices and were damaged thereby.

27 53. At the time of said misrepresentations and/or omissions, Plaintiff and other members
28 of the Class were ignorant of their falsity, and believed them to be true. Had Plaintiff and the other

1 members of the Class and the marketplace known the truth regarding the problems that Hims was
2 experiencing, which were not disclosed by Defendants, Plaintiff and other members of the Class
3 would not have purchased or otherwise acquired their Hims securities, or, if they had acquired such
4 securities during the Class Period, they would not have done so at the artificially inflated prices
5 which they paid.

6 54. By virtue of the foregoing, Defendants violated Section 10(b) of the Exchange Act
7 and Rule 10b-5 promulgated thereunder.

8 55. As a direct and proximate result of Defendants' wrongful conduct, Plaintiff and the
9 other members of the Class suffered damages in connection with their respective purchases and
10 sales of the Company's securities during the Class Period.

11 **SECOND CLAIM**

12 **Violation of Section 20(a) of The Exchange Act**

13 **Against the Individual Defendants**

14 56. Plaintiff repeats and re-alleges each and every allegation contained above as if fully
15 set forth herein.

16 57. Individual Defendants acted as controlling persons of Hims within the meaning of
17 Section 20(a) of the Exchange Act as alleged herein. By virtue of their high-level positions and their
18 ownership and contractual rights, participation in, and/or awareness of the Company's operations
19 and intimate knowledge of the false financial statements filed by the Company with the SEC and
20 disseminated to the investing public, Individual Defendants had the power to influence and control
21 and did influence and control, directly or indirectly, the decision-making of the Company, including
22 the content and dissemination of the various statements which Plaintiff contends are false and
23 misleading. Individual Defendants were provided with or had unlimited access to copies of the
24 Company's reports, press releases, public filings, and other statements alleged by Plaintiff to be
25 misleading prior to and/or shortly after these statements were issued and had the ability to prevent
26 the issuance of the statements or cause the statements to be corrected.

27 58. In particular, Individual Defendants had direct and supervisory involvement in the
28 day-to-day operations of the Company and, therefore, had the power to control or influence the

1 particular transactions giving rise to the securities violations as alleged herein, and exercised the
2 same.

3 59. As set forth above, Hims and Individual Defendants each violated Section 10(b) and
4 Rule 10b-5 by their acts and omissions as alleged in this Complaint. By virtue of their position as
5 controlling persons, Individual Defendants are liable pursuant to Section 20(a) of the Exchange Act.
6 As a direct and proximate result of Defendants' wrongful conduct, Plaintiff and other members of
7 the Class suffered damages in connection with their purchases of the Company's securities during
8 the Class Period.

9 **PRAYER FOR RELIEF**

10 WHEREFORE, Plaintiff prays for relief and judgment, as follows:

11 (a) Determining that this action is a proper class action under Rule 23 of the Federal
12 Rules of Civil Procedure;

13 (b) Awarding compensatory damages in favor of Plaintiff and the other Class members
14 against all defendants, jointly and severally, for all damages sustained as a result of Defendants'
15 wrongdoing, in an amount to be proven at trial, including interest thereon;

16 (c) Awarding Plaintiff and the Class their reasonable costs and expenses incurred in this
17 action, including counsel fees and expert fees; and

18 (d) Such other and further relief as the Court may deem just and proper.

19 **JURY TRIAL DEMANDED**

20 Plaintiff hereby demands a trial by jury.
21
22
23
24
25
26
27
28